Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2007

View Archived Issues

Neogenix selects GBI to manufacture its monoclonal antibody, NPC-1C

HemispheRx initiates Ampligen phase IIb trial for seasonal flu in Australia

Promising antitumor activity of thorium-labeled rituximab

Lupulone shows antiangiogenic activity in vitro and in vivo

Preliminary phase III results for CellCept in lupus nephritis

Alnylam advances RNAi therapeutic program into IND-enabling studies

Positive phase IIa results for Speedel's renin inhibitor for hypertension

Kythera completes enrollment for phase II trial of ATX-201

Roche and Merck & Co. patents report new agents for depression, psychosis and sleep disorders

Delcath includes fourth arm to phase II study of metastatic melanoma

New diagnostic agents reported by the Universities of Pittsburgh and Hong Kong

Acadia initiates phase IIb trial of ACP-104 for schizophrenia

Wilex begins enrollment for phase II trial for pancreatic cancer

New agents for endocrine-related disorders imparted in recent patent literature

FDA grants fast track designation for HCV-796

Alnylam initiates phase II trial of ALN-RSV01 for RSV

Organon signs asset purchase agreement for Kadmus' FAAH technology

New phase III trial studies sunitinib malate in metastatic colorectal cancer

Wyeth licenses osteoporosis drug targets from Galapagos collaboration

Largest international study of patients on dialysis begins in Europe

NanoEmulsion diclofenac cream begins phase IIa study

Amendment to Lialda agreement

Schering-Plough will not enter new exclusivity period to negotiate celgosivir license

Highly immunogenic ribosomal-based vaccine protects against Shigella infection

CH-1504 begins bioequivalence study

Priority review for Taxotere sNDA in head and neck cancer

ALT-2074 begins phase II study in patients with diabetes and Hp2-2

Vyvanse filed for ADHD in adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...